<DOC>
	<DOCNO>NCT02704741</DOCNO>
	<brief_summary>The CO2RE laser system fractional CO2 laser FDA approve 510 ( k ) K101321 dermatologic procedure require ablation coagulation soft tissue , include skin Eligible subject undergo 3 treatment 4±1 week interval Vagina ( External/Vulva Internal/Vagina ) CO2RE device accord study protocol . Subject return 5 follow-up ( FU ) visit : 1 week ± 2 day post first treatment visit 1 , 3 , 6 12 month last ( third ) treatment ( ± 2 week ) . Methodology describe protocol evaluate efficacy treatment carry visit clinic .</brief_summary>
	<brief_title>Clinical Study CO2RE Laser Device Performance Vaginal Atrophy Treatments</brief_title>
	<detailed_description>This study Prospective clinical study demonstrate CO2RE laser device safety efficacy Vaginal Atrophy . Up total 60 healthy candidate , seek vaginal treatment participate investigator enrol participate study site . Subjects receive three ( 3 ) CO2RE treatment . Each subject follow additional 5 post treatment visit ( FU visit ) conduct : - One week post first treatment - 1wk FU ± 2 day ( Safety ) . - 1 month post last treatment - 1m FU ± 2 week ( efficacy &amp; Safety ) . - 3 month post last treatment - 3m FU ± 2 week ( efficacy &amp; Safety ) . - 6 month post last treatment - 6m FU ± 2 week ( efficacy &amp; Safety ) . - 12 month post last treatment - 12m FU ± 2 week ( efficacy &amp; Safety ) .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<criteria>1 . Subjects seek treatment Vaginal Atrophy vagina area ( External vestibule introitus ; Internal Vaginal canal ) 2 . Healthy female subject age great equal 35 year age post menopausal least one year , reason whether surgical , chemical natural . 3 . Absence menstruation least 12 month 4 . Not respond satisfy previous local estrogen therapy 5 . Desire maintain sexual activity 6 . Informed consent process complete subject sign consent 7 . Willing receive propose CO2RE treatment followup protocol 8 . Postmenopausal surgically sterilize . 9 . Normal cell cytology ( PAP smear ) 10 . Negative urinalysis normal vaginal canal ( evidence dysplasia occult active infection ) 11 . The external vaginal area ( vestibule introitus ) free injury bleed 12 . Subject experienced sexual activity least month 1 . Subject surgery procedure Vaginal Tightening last 12 month 2 . Use hormone replacement therapy , either systemic local within last 6 month prior study 3 . Lubricants localize preparation 30 day prior enrollment 4 . Patient history herpes . 5 . Acute recurrent urinary tract infection ( UTI ) genital infection ( e.g . herpes , candida ) 6 . Active malignancy history malignancy past 5 year 7 . Having active electrical implant anywhere body , pacemaker internal defibrillator 8 . Suffering significant concurrent illness , cardiac disorder , diabetes ( type I II ) , lupus , porphyria , pertinent neurological disorder ( i.e . disease state opinion Physician would interfere treatment , heal process ) 9 . Having know anticoagulative thromboembolic condition take anticoagulation medication one week prior treatment course ( allow inclusion , temporary cessation use per subject 's physician discretion ) 10 . History immunosuppression/immune deficiency disorder ( include HIV infection AIDS ) currently use immunosuppressive medication 11 . Suffering hormonal imbalance , whether related thyroid , pituitary , androgen 12 . History significant lymphatic drainage problem 13 . History cancer require lymph node biopsy dissection 14 . Suffering significant condition treat area inflammatory condition , include , limited , open laceration abrasion treatment area prior treatment ( duration resolution per Investigator 's discretion ) treatment course 15 . History keloid scarring , abnormal wound heal / prone bruise 16 . History epidermal dermal disorder ( particularly involve collagen microvascularity ) , include collagen vascular disease vasculitic disorder 17 . Use isotretinoin ( Accutane® ) within 6 month treatment study 18 . Subject systemic corticosteroid therapy 6 month prior throughout course study 19 . Dysplastic nevi area treat 20 . Participation study another device drug within 6 month prior enrollment study , treatment vagina involved 21 . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study 22 . Prolapse stag &gt; _ II , accord pelvic organ prolapse quantification ( ICSPOPQ ) system 23 . Previously undergone pelvic reconstructive surgery</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>